Quantum Biopharma Class B Subordinate Voting Shares
QNTM
17 hedge funds and large institutions have $515K invested in Quantum Biopharma Class B Subordinate Voting Shares in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 6 closing their positions.
117% more call options, than puts
Call options by funds: $804K | Put options by funds: $370K
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
2.25% less ownership
Funds ownership: 3.05% → 0.8% (-2.2%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
73% less capital invested
Capital invested by funds: $1.91M → $515K (-$1.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$69.3K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$28.5K |
| 3 |
RM
Resource Management
Metairie,
Louisiana
|
+$22.5K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
+$19.4K |
| 5 |
Millennium Management
New York
|
+$16.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$1.01M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$233K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$145K |
| 4 |
RPC
Rossmore Private Capital
Glastonbury,
Connecticut
|
-$40K |
| 5 |
VF
Virtu Financial
New York
|
-$29K |
QNTM Hedge Fund Activity: Q3 2021 in Review
17 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q3 2021, worth a combined $515K — down 73% from $1.91M a quarter earlier.
Fund positioning in QNTM was balanced in Q3 2021: 6 funds opened new positions, 6 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Vident Investment Advisory, opening a new position worth an estimated $69.3K. The largest seller was IQ EQ Fund Management, exiting entirely with an estimated $1.01M sold.
- 17 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $515K of Quantum Biopharma Class B Subordinate Voting Shares stock for Q3 2021, down 73% quarter-over-quarter.
- 6 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q3 2021 and 6 closed out, a net change of 0 holders.
- The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q3 2021 was Vident Investment Advisory, an estimated $69.3K added.
- The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q3 2021 was IQ EQ Fund Management, an estimated $1.01M sold.
Based on aggregated 13F filings for Q3 2021.